Bristol Myers Squibb (BMY) Receivables - Net (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Receivables - Net for 18 consecutive years, with $10.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Net fell 7.55% year-over-year to $10.6 billion in Q2 2026; TTM through Jun 2026 was $10.6 billion, a 7.55% decrease from a year earlier, with the FY2025 full-year figure at $11.4 billion, up 6.21% from the prior year.
• Receivables - Net was $10.6 billion for Q2 2026 at Bristol Myers Squibb, up from $9.4 billion in the prior quarter.
• Over five years, Receivables - Net peaked at $11.4 billion in Q2 2024 and troughed at $8.5 billion in Q1 2022.
• A 5-year average of $10.4 billion and a median of $10.5 billion in 2024 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net increased 18.13% in 2023 and slipped 13.27% in 2026, its largest moves.
• Over 5 years, Receivables - Net stood at $9.9 billion in 2022, then increased by 10.47% to $10.9 billion in 2023, then decreased by 1.59% to $10.7 billion in 2024, then advanced by 6.21% to $11.4 billion in 2025, then fell by 7.54% to $10.6 billion in 2026.
• The last three Receivables - Net figures came in at $10.6 billion (Q2 2026), $9.4 billion (Q1 2026), and $11.4 billion (Q4 2025), per Business Quant data.